$AIAI

Liebman Stephanie sold $382K of AIAI

Liebman Stephanie (EVP/CFO) sold 26,177 shares of AIAI Holdings Corp (AIAI) at an average of $14.58 ($14.21–$15.62, $0.38M total) across 4 trades over 2026-06-26 to 2026-06-30.

Original reporting
SEC EDGAR · Liebman Stephanie
Published Jul 1, 2026, 12:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 12:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AIAI
Neutral
medium confidence
Mentioned
$AIAI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIAINeutralLow
01

Why it matters

The disclosure updates the insider-trading record for AIAI’s CFO, which can influence short-term sentiment but does not provide new operational or financial guidance.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

Form 4 sales often occur for tax/estate planning; without context on total compensation, prior sale patterns, or concurrent buys, the signal is weak.

Relevance 4/10Novelty 5/10Timing: filed 2026-06-30 after trades from 2026-06-26 to 2026-06-30

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for AIAI Holdings Corp.

Company-level read

Ticker impact

$AIAINeutralMedium confidence
Context

SEC Form 4 shows AIAI CFO sold 26,177 shares in open-market transactions for about $381,645, with no 10b5-1 plan cited.

Expected impact

Likely limited, short-lived impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

The filing is a primary-source Form 4, but it is a routine open-market sale and the article provides no accompanying company-specific catalyst (earnings, guidance, deal, or investigation).

Market effects

No sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

The sale may be planned for liquidity or diversification; absence of a 10b5-1 plan does not necessarily imply negative information.

Key entities

  • AIAI Holdings Corp

    Subject of the Form 4 insider transaction; CFO sold shares in open-market trades.

  • Stephanie Liebman

    EVP/CFO who reported the sale of 26,177 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AIAIMed

AIAI Holdings Announces Letter of Intent with Messier 42 LLC to Acquire Controlling Interest in Defense & National Security Company

AIAI Holdings (NASDAQ:AIAI) has signed a letter of intent to acquire a controlling stake in a defense company from Messier 42 LLC. The target is projected to generate $250M in free cash flow annually post-closing. The deal, expected to close in Q4 2026, is subject to due diligence, board approvals, and a fairness opinion.

$AIAIMed

AIAI Holdings' Constellation Network Unveils Gate AI Security Gateway and Performance Benchmarks Ahead of June Launch

AIAI Holdings said its portfolio company Constellation Network will launch Constellation Gate AI, an AI security and audit gateway, in June 2026. Constellation’s technical report evaluated prompt-injection defenses across 16 public datasets, reporting an F1 of 97.4% at a 1% false-positive rate and top rankings on 8 datasets. It also cited median response time of 53 ms.

$AIAIMed

AIAI Holdings' Constellation Network Unveils Gate AI Security Gateway and Performance Benchmarks Ahead of June Launch

AIAI Holdings said its portfolio company Constellation Network will launch Constellation Gate AI in June 2026. A technical report, according to Constellation, found Gate AI ranked first on 8 of 16 public prompt-injection benchmark datasets and top three on 4 more, with an F1 of 97.4% at a 1% false-positive rate and median response time of 53 ms.